Barr Laboratories Articles
AstraZeneca unit MedImmune in-licenses anti-inflammatory MAb from Amgen; latter’s Sensipar patent upheld
10 January 2011
Merck & Co prevails in Temodar law suit against Barr/Teva on appeal; Court upholds Shire’s Vyvanse exclusivity
11 November 2010
Shire sues Barr over Fosrenol patents
23 March 2009
Shire told Mylan and Barr seeking generic Fosrenol appro
16 February 2009
Warner Chilcott and Barr settle Femcon dispute
12 January 2009
Court of Appeal upholds 2005 Barr/Cipro decision
27 October 2008
Barr gets FDA clearance for generic Razadyne
22 September 2008
Ortho-McNeil to appeal Razadyne patent ruling
8 September 2008
Barr Labs challenges FazaClo patents
1 September 2008
Germany's Stada on acquisitoin trail
1 September 2008
Barr confirms Sensipar patent challenge
4 August 2008
Barr confirms Entocort patent challenge
2 June 2008
Senior management changes at Barr
7 April 2008
US court rules patent for Yasmin is invalid
10 March 2008
Barr challenges GSK's Avodart patent
3 March 2008
FDA sues Cephalon for generic blocking
25 February 2008
Barr confirms Namenda patent challenge
21 January 2008
Barr Labs challenges Argatroban patent
7 January 2008
Barr's generic Kytril gains final FDA approval
7 January 2008
US FTC settles with Barr Labs over Ovcon
10 December 2007
Reverse payment ban stalls in US Congress
19 November 2007
Barr confirms patent challenge to Novartis Ritalin
12 November 2007
FDA clears Barr's generic Estrostep
5 November 2007
Barr's Portia approved and launched in Canada
3 September 2007
Schering-Plough to sue Barr on generic Temodar
30 July 2007
Barr challenges Boeh Ing's Aggrenox patent
23 July 2007
Barr confirms Xoprenex patent challenge
23 July 2007
Barr drops challenge on Lilly's US Zyprexa patent
18 June 2007
FDA OKs Barr's generic Nimotop
7 May 2007
Barr confirms Ambien patent challenge
16 April 2007
Barr challenges Otsuka's Abilify patent
26 March 2007
Savient files patent suit against Sandoz
11 December 2006
Mangement changes at Pliva following acquisition by Barr
6 November 2006
Actavis bows out of bidding for Pliva leaving field open for Barr's offer to go through
25 September 2006
Now US anti-abortion groups block FDA appointment
28 August 2006
$150,000 to Clinton from 'price-gouging' pharma
24 July 2006
Fentora viewed as approvable by US FDA
10 July 2006
FDA's Plan B refusal continues political storm
26 June 2006
Is Barr Labs competing for Pliva?
5 June 2006
Stock Commentary - New York week to May 22, 2006
29 May 2006
Barr challenges Nasacort patent
15 May 2006
Only Actavis seems to be interested in Pliva
15 May 2006
Barr sees 85.2% leap in EPS for full fiscal year
19 September 2005
Stock Commentary - New York week toSept 12
19 September 2005
Stock Commentary - Europe - week to Sept 12
19 September 2005
Barr gets final US appro for generic Allegra
5 September 2005
Barr Labs profiled by R&M
23 May 2005
Stock Commentary - New York
16 May 2005
Barr gets FDA approval for generic Niaspan
9 May 2005
Barr eligible for exclusivity on generic Allegra-D
18 April 2005
Update on Barr/Aventis Allegra patent dispute
11 April 2005
Barr confirms filing in USA for Yasmin
4 April 2005
IMPAX intervenes in Barr litigation
7 March 2005
Barr sues FDA over generic Allegra
14 February 2005
Barr confirms challenge to Zyprexa patent
13 December 2004
Barr's 1st-qtr profit up despite sales decline
15 November 2004
New schedule for Kos/Barr litigation
1 November 2004
UPDATE: Ireland's Warner Chillcott mulls L1.7 billion offer from private equity group
27 September 2004
Stock Commentary - New York
16 August 2004
Stock Commentary - New York
12 July 2004
Stock Commentary - Europe
12 July 2004
Barr and Pfizer win patent litigations
12 July 2004
Stock Commentary - New York
5 July 2004
Stock Commentary - New York
21 June 2004
Schering AG and Barr in oxybutynin deal
12 April 2004
Blending of branded and generic pharma: a rising trend?
12 April 2004
Kos takes Barr to court over Niaspin patent
12 April 2004
Barr and Galen announce Loestrin and Ovcon 35 deals
5 April 2004
Agis considers sale of activities for $900M
1 March 2004
Barr completes reincorporation from New York to Delaware
5 January 2004
Barr receives approval for generic Larium
5 January 2004
Barr introduces generic Tri-Cyclen
5 January 2004
Barr to acquire Endeavor Pharma assets
15 December 2003
Shire's Adderall XR facing further generic comp
24 November 2003
Adderall XR on track for US use in adults
27 October 2003
Barr to swallow Pan-B for $20 million
13 October 2003
Stock Commentary - Europe
22 September 2003
Barr Labs and Galen in oral contraceptives licensing deal
22 September 2003
Barr's Seasonale gets approval from FDA
15 September 2003
Shire files key law suit against Barr Labs
8 September 2003
Stock Commentary - New York
11 August 2003
Bayer's profits tumble in second quarter
11 August 2003
Stock Commentary - New York
28 July 2003
Galen Merger talks terminated
28 July 2003
Stock Commentary - Europe
28 July 2003
Barr Labs dedicates adenovirus facility
14 July 2003
Stock Commentary - New York
23 June 2003
Barr completes deal to acquire Wyeth prods
16 June 2003
Barr begins shipping ciprofloxacin
16 June 2003
Stock Commentary - New York
2 June 2003
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
